- cafead May 18, 2023 at 11:22: AM
via Amid a wave of patent litigation over Johnson & Johnson's portfolio of schizophrenia treatments, the company has successfully batted away a copycat challenge from Viatris.
Viatris’ proposed generics of J&J’s long-lasting Invega Trinza would "induce infringement" of the so-called '693 patent, New Jersey District Judge Evelyn Padin wrote in court documents filed this week. Viatris’ attempts to show the patent is invalid have fallen flat, Padin continued.
article source
Viatris’ proposed generics of J&J’s long-lasting Invega Trinza would "induce infringement" of the so-called '693 patent, New Jersey District Judge Evelyn Padin wrote in court documents filed this week. Viatris’ attempts to show the patent is invalid have fallen flat, Padin continued.
article source